Abstract:Glucagon-like peptide-1 (GLP-1) receptor agonists are new anti-diabetic agents. They show the beneficial metabolic effects such as lowering blood glucose, reducing body weight, lowering blood pressure and improving lipid profiles. Moreover, they also have the protective effects on several organs or tissues including cardiovascular system, kidney and brain. Recently, Chinese researchers have gained abundant data in clinical and basic studies on GLP-1 receptor agonists for treating diabetes. Here we summarize the progress about this study field in China.

Clinical and Basic Studies of GLP-1 Receptor Agonists for the Treatment of Diabetes in China